Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.

MLA

Jerusalem, Guy, et al. “Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.” JAMA Oncology, vol. 4, no. 10, Oct. 2018, pp. 1367–74. EBSCOhost, https://doi.org/10.1001/jamaoncol.2018.2262.

APA

Jerusalem, G., de Boer, R. H., Hurvitz, S., Yardley, D. A., Kovalenko, E., Ejlertsen, B., Blau, S., Özgüroglu, M., Landherr, L., Ewertz, M., Taran, T., Fan, J., Noel-Baron, F., Louveau, A.-L., & Burris, H. (2018). Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial. JAMA Oncology, 4(10), 1367–1374. https://doi.org/10.1001/jamaoncol.2018.2262

Chicago

Jerusalem, Guy, Richard H de Boer, Sara Hurvitz, Denise A Yardley, Elena Kovalenko, Bent Ejlertsen, Sibel Blau, et al. 2018. “Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.” JAMA Oncology 4 (10): 1367–74. doi:10.1001/jamaoncol.2018.2262.